Royalty Pharma plc Earnings Recaps
Q1 2026
May 7, 2026
Royalty Pharma’s shares declined modestly by 0.5% following an earnings report that showed steady growth but lacked new positive catalysts to drive the stock higher. While the company reiterated double-digit portfolio growth and raised full-year guidance, investors appeared cautious given the absence of upside surprises.
Key takeaways
- Portfolio receipts grew 10% year-over-year, driven by diversified asset base; recurring royalty receipts increased 13%.
- Returned capital efficiently with returns on invested capital around 14% and invested equity near 20%.
- Deployed over $0.5 billion in capital including $1.25 billion in announced transactions on three therapies; also repurchased 1 million shares and raised dividend by 7%.
- Highlighted progress in R&D co-funding with large biopharma partners such as J&J and Teva, illustrating a strategic shift toward synthetic royalties and innovative funding structures.
- Incremental full-year guidance was raised, supported by a pipeline of clinical and regulatory developments, though the market reaction suggests limited incremental confidence.
Q3 2025
Nov 6, 2025
Royalty Pharma reported a robust third quarter, achieving 11% growth in both portfolio and royalty receipts, alongside strong capital deployment, further solidifying its position in the life sciences sector.
Key takeaways
- Achieved 11% growth in both portfolio and royalty receipts, reflecting the strength of a diversified portfolio.
- Deployed $1 billion in capital this quarter, bringing total deployments to $1.7 billion for the year, while repurchasing 4 million shares.
- Expanded development-stage pipeline to 17 therapies, with multiple pivotal readouts expected soon.
- Raised full-year 2025 portfolio receipts guidance again, now projecting growth of 14% to 16%, totaling between $3.2 billion and $3.25 billion.
- Committed over $1.6 billion in recent transactions, enhancing growth prospects in key therapeutic areas.